Novel non-steroidal/non-anilide type androgen antagonists with an isoxazolone moiety (Q40745496)

23 September 2017

title

Novel non-steroidal/non-anilide type androgen antagonists with an isoxazolone moiety (English)

1 reference

23 September 2017

Toshiyasu Ishioka

1

1 reference

23 September 2017

Asako Kubo

2

1 reference

23 September 2017

Yukiko Koiso

3

1 reference

23 September 2017

Kazuo Nagasawa

4

1 reference

23 September 2017

Akiko Itai

5

1 reference

23 September 2017

Yuichi Hashimoto

6

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

Bioorganic & Medicinal Chemistry

23 September 2017

published in

1 reference

23 September 2017

volume

10

1 reference

23 September 2017

issue

5

1 reference

23 September 2017

page(s)

1555-1566

1 reference

Biological Actions of Androgens

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Gene regulation through chromatin remodelling by members of the nuclear receptor superfamily

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Localization of functional domains in the androgen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Retinobenzoic acids and nuclear retinoic acid receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

A canonical structure for the ligand-binding domain of nuclear receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Pharmacology and Potential Use of Cyproterone Acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

How the study of the biological activities of antiandrogens can be oriented towards the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Androgen receptor antagonists (antiandrogens): structure-activity relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Anti-Androgenicity of Flutamide and its Metabolite Sch 16423

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

The pure antiandrogen ru 23908 (anandron®), a candidate of choice for the combined antihormonal treatment of prostatic cancer: A review

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Structural development of biological response modifiers based on thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Anti-androgenic activity of substituted azo- and azoxy-benzene derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071).

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Suramin interrupts androgen‐inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Expression and characterization of full-length and partial human androgen receptor fusion proteins. Implications for the production and applications of soluble steroid receptors in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Mouse fibroblast growth factor 10: cDNA cloning, protein characterization, and regulation of mRNA expression

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Fluorescent and photoaffinity labeling derivatives of rhizoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Identification of the fragment photoaffinity-labeled with azidodansyl-rhizoxin as Met-363-Lys-379 on beta-tubulin

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

Enantioselective binding of Casodex to the androgen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2801%2900421-7

7 January 2021

10.1016/S0968-0896(01)00421-7

Identifiers

DOI

1 reference

23 September 2017

1 reference